Komori
General Meetings of Shareholders4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Convocation of the 2024 Annual General Meeting of Shareholders

For the 129th Annual General Meeting of Shareholders, the Company submitted 3 company proposals and 6 shareholder proposals. The shareholder proposals include the appropriation of surplus, amendments to the Articles of Incorporation, and the reversal of a separate reserve. The Board of Directors opposes all of them.

Worth reading
79Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
9
議案（会社提案3件、株主提案6件）
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (129th)
2024年
6月27日
Date and time（木曜日）午前10時27 days from this disclosure to the meeting
Matters for resolution9 items (7 from the company, 2 from shareholders)

  1. Appropriation of surplus

  2. Election of 6 directors, excluding directors who are Audit & Supervisory Committee Members

  3. Election of 1 director who is an Audit & Supervisory Committee Member

  4. 別途積立金取崩しの件

    Shareholder Proposal

  5. 剰余金処分の件

  6. 実験動物の動物別購入頭数の開示を定款目的事項へ追加する定款一部変更の件

  7. 政策保有株式にかかる温室効果ガス排出量持分に関する定款一部変更の件

  8. 有価証券報告書の定時株主総会前提出に関する定款一部変更の件

  9. 資本コストや株価を意識した経営の実現に向けた対応の開示に関する定款一部変更の件

    Shareholder Proposal
Shareholder Proposal

提案者の個人名はNot disclosed。第4号議案から第9号議案までが株主提案で、取締役会はいずれにも反対。

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee7名（第2号議案6名、第3号議案1名）。新任3名、社外1名。
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (129th)
Date and time2024年6月27日（木曜日）午前10時
Matters for resolutionProposal No. 1: Appropriation of surplus, Proposal No. 2: Election of 6 directors, excluding directors who are Audit & Supervisory Committee Members, Proposal No. 3: Election of 1 director who is an Audit & Supervisory Committee Member, 第4号議案 別途積立金取崩しの件, 第5号議案 剰余金処分の件, 第6号議案 実験動物の動物別購入頭数の開示を定款目的事項へ追加する定款一部変更の件, 第7号議案 政策保有株式にかかる温室効果ガス排出量持分に関する定款一部変更の件, 第8号議案 有価証券報告書の定時株主総会前提出に関する定款一部変更の件, 第9号議案 資本コストや株価を意識した経営の実現に向けた対応の開示に関する定款一部変更の件
Shareholder Proposal提案者の個人名はNot disclosed。第4号議案から第9号議案までが株主提案で、取締役会はいずれにも反対。
Director nominee7名（第2号議案6名、第3号議案1名）。新任3名、社外1名。
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

株主提案について、提案株主は株主還元の強化、資本効率や株主価値の改善、実験動物に関する情報開示、気候変動対応などを理由としている。取締役会は、成長投資・財務の安定性・機動的な経営判断を重視し、各株主提案に反対している。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2024 Annual General Meeting of Shareholders | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori